

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT5599452

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
BARR LABORATORIES, INC.	06/28/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	CLEXIO BIOSCIENCES LTD.
<b>Street Address:</b>	21 NAHUM HAFTZADI STREET
<b>Internal Address:</b>	GIVAT SHAUL
<b>City:</b>	JERUSALEM
<b>State/Country:</b>	ISRAEL
<b>Postal Code:</b>	9123901
<b>PROPERTY NUMBERS Total: 7</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	14757954
Application Number:	16025009
PCT Number:	US2018040536
Application Number:	62692904
Application Number:	62692987
Application Number:	62693087
Application Number:	62692959
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	215-564-3100
<b>Email:</b>	patents@bakerlaw.com
<b>Correspondent Name:</b>	BAKER & HOSTETLER LLP
<b>Address Line 1:</b>	2929 ARCH STREET
<b>Address Line 2:</b>	CIRA CENTRE, 12TH FLOOR
<b>Address Line 4:</b>	PHILADELPHIA, PENNSYLVANIA 19104
<b>ATTORNEY DOCKET NUMBER:</b>	101889.000001
<b>NAME OF SUBMITTER:</b>	MAURA Q RYAN
<b>SIGNATURE:</b>	/Maura Q. Ryan/

PATENT

<b>DATE SIGNED:</b>	07/01/2019
---------------------	------------

**Total Attachments: 4**

source=101889\_000470\_Executed\_Assignment\_-\_Barr\_to\_Clexio#page1.tif

source=101889\_000470\_Executed\_Assignment\_-\_Barr\_to\_Clexio#page2.tif

source=101889\_000470\_Executed\_Assignment\_-\_Barr\_to\_Clexio#page3.tif

source=101889\_000470\_Executed\_Assignment\_-\_Barr\_to\_Clexio#page4.tif

**ASSIGNMENT**

WHEREAS, **BARR LABORATORIES, INC.** (hereinafter referred to as the ASSIGNOR), having its principal place of business at **400 Interpace Parkway, Bldg. A., Parsippany, New Jersey 07054**, is the owner of certain inventions that are the subject of the patents and/or patent applications set forth in Appendix A to this assignment, which inventions, patents and patent applications will be referred to herein as the "Patent Property" and/or the "Patent Properties"; and

WHEREAS, **CLEXIO BIOSCIENCES LTD.** (hereinafter referred to as the ASSIGNEE), having its principal place of business at **21 Nahum Haftzadi Street, Givat Shaul, Jerusalem 9123901, Israel**, is desirous of acquiring the entire right, title and interest in and to the said Patent Property in any and all countries;

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, and intending to be legally bound hereby, ASSIGNOR has sold, assigned, transferred and set over, and by these presents does hereby sell, assign, transfer and set over to said ASSIGNEE, the entire right, title and interest in and to said Patent Property and any and all continuations, continuation-in-part, divisions and renewals of and substitutes for said Patent Property and to and under any and all additional Letters Patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissue or reissues or extension or extensions of said Letters Patent, and the full right to sue for and recover damages recoverable for past infringement of the same, and for violations of provisional rights having arisen from any published application(s) for said Patent Property, and all the rights, privileges, and benefits therein, including any and all rights, privileges and benefits under the Paris Convention for the Protection of Industrial Properties, including the right to claim priority based on the Patent Property, and any and all continuations, divisions and renewals of and substitute for said Patent Property. ASSIGNOR further assigns to and authorizes said ASSIGNEE to file corresponding applications for Letters Patent in all countries, to be held and enjoyed by said ASSIGNEE, its successors, assigns, nominees or legal representatives, to the full end of the term or terms for which said Letters Patent respectively may be granted, reissued or extended, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this assignment, sale and transfer not been made.

It is hereby covenanted that ASSIGNOR has full right to convey the entire interest herein assigned, and that ASSIGNOR has not executed and will not execute any agreement in conflict herewith, and ASSIGNOR further covenants and agrees that it will each time request is made and without undue delay,

delay, execute and deliver all such papers as may be necessary or desirable to perfect the title to said Patent Property in said assignee, its successors, assigns, nominees, or legal representatives, and ASSIGNOR agrees to communicate to said ASSIGNEE or to its nominee all known facts respecting said Patent Property, to testify in any legal proceedings, to sign all lawful papers to execute all disclaimers and divisional, continuing, reissue and foreign applications, to make all rightful oaths, and generally to do everything reasonably possible to aid said ASSIGNEE, its successors, assigns, nominees and legal representatives to obtain and enforce for its or their own benefit proper patent protection for said inventions or improvements in any and all countries, all at the expense, however, of said ASSIGNEE, its successors, assigns, nominees or legal representatives.

AND ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue to said ASSIGNEE, as assignee of the entire right, title and interest, any and all Letters Patent for said Patent Property, including any and all Letters Patent of the United States which may be issued and granted on or as a result of any applications included in said Patent Property, in accordance with the terms of this assignment.

IN WITNESS WHEREOF, the undersigned, being properly authorized to execute this Assignment, hereunto sets their hand and seal.

ASSIGNOR:  
BARR LABORATORIES, INC.

ASSIGNEE:  
CLEXIO BIOSCIENCES LTD.

By:   
(Name) Brian E. Shanahan  
Secretary

By: \_\_\_\_\_  
(Name)

Its: \_\_\_\_\_  
(Title)

Its: \_\_\_\_\_  
(Title)

Date: June 28, 2019

Date: \_\_\_\_\_

execute and deliver all such papers as may be necessary or desirable to perfect the title to said Patent Property in said assignee, its successors, assigns, nominees, or legal representatives, and ASSIGNOR agrees to communicate to said ASSIGNEE or to its nominee all known facts respecting said Patent Property, to testify in any legal proceedings, to sign all lawful papers to execute all disclaimers and divisional, continuing, reissue and foreign applications, to make all rightful oaths, and generally to do everything reasonably possible to aid said ASSIGNEE, its successors, assigns, nominees and legal representatives to obtain and enforce for its or their own benefit proper patent protection for said inventions or improvements in any and all countries, all at the expense, however, of said ASSIGNEE, its successors, assigns, nominees or legal representatives.

AND ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue to said ASSIGNEE, as assignee of the entire right, title and interest, any and all Letters Patent for said Patent Property, including any and all Letters Patent of the United States which may be issued and granted on or as a result of any applications included in said Patent Property, in accordance with the terms of this assignment.

IN WITNESS WHEREOF, the undersigned, being properly authorized to execute this Assignment, hereunto sets their hand and seal.

**ASSIGNOR:**  
**BARR LABORATORIES, INC.**

**ASSIGNEE:**  
**CLEXIO BIOSCIENCES LTD.**

By: \_\_\_\_\_  
(Name)

By: Elizabeth Kagan  
(Name)

Its: \_\_\_\_\_  
(Title)

Its: CEO  
(Title)

Date: \_\_\_\_\_

Date: 27/6/2019

APPENDIX A

<u>Teva Ref.</u>	<u>Application No.</u>	<u>Filing Date</u>	<u>Grant No.</u>	<u>Title</u>
PTV061-US	14/757,954	12/23/2015	10,010,543	Transdermal Dosage Form
PTV061-A-US	16/025,009	07/02/2018		Transdermal Dosage Form
PTV061-A-PCT	PCT/US2018/040536	07/02/2018		Transdermal Dosage Form
PTV247-P1	62/692,904	07/02/2018		Abuse Deterrent Transdermal Dosage Form
PTV260-P1	62/692,987	07/02/2018		Process for Manufacture of Transdermal Dosage Forms
PTV257-P1	62/693,087	07/02/2018		Transdermal Dosage Forms
PTV258-P1	62/692,959	07/02/2018		Abuse Deterrent Transdermal Dosage Form